Bio-Techne vs. the Research Tools Field: Who Actually Won Q2?

The Q2 recaps for research tools & consumables put Bio-Techne's (NASDAQ: TECH) name on the winner side of the board. Run the same quarter as a controlled race — Bio-Techne against the rest of the field — and a different verdict falls out. The company that looked like Q2's standout did not win the quarter on operations. It won on one Thursday morning in June, when somebody bought it.

The card

Same bell, same clock, one question: does this quarter belong to TECH, or to the field that trades around it?

• Contestant A: Bio-Techne (TECH) — the antibodies, proteins, and spatial-biology tools maker reporting roughly $1.2 billion a year.
• Contestant B: "The Rest" — an equal-weight basket of the seven publicly listed names the sector's own screens group with TECH: Thermo Fisher, Danaher, Waters, Revvity, Sotera Health, Avantor, and Bruker.
• Start: both at 100 paper points, priced off the December 31, 2025 close.
• Finish and score: price return observed at the September 1, 2026 session, both sides read from the same market-data feed at the same timestamp. Equal weight, no rebalancing. Dividends are omitted — the whole field yields under roughly 1%, immaterial over an eight-month window.
• Corporate action: June 25, 2026. The frozen exit protocol governs here, not the winner column: when a contestant accepts a cash bid, its remaining shares are adjudicated at the consideration, and the race is split into pre-bid and post-bid phases.
• Opening odds, declared before kickoff: The Rest, 58/42. Rationale: TECH's price upside was already capped by a signed bid at the bell, while the field's operators still had uncapped quarterly compounding in front of them.
• Checkpoints: quarterly, and at any material corporate action. If the bid closes, TECH converts to $73 cash and the score is adjudicated as written; if it terminates, the race reopens at the next tradable close.

The pregame read, for the record: The Rest goes in with the growth edge; TECH goes in with the margin edge — about 32% adjusted operating margin — and the least forward optionality, because its equity is already sold.

Scoreboard: a nine-point lead that is really one day

At the first checkpoint the price board does show TECH ahead: 123 paper points to The Rest's 114. Then read the ledger.

Through the last session before the bid, TECH had returned roughly zero for the year. The bridge is reproducible: TECH closed June 24 near $58.88 (backed out of the 20.02% jump to $70.67 on the 25th) against an implied 2025 close of about $58.81 — flat. Then Merck KGaA — the German science-and-technology company, not the U.S. drugmaker Merck — agreed to pay $73 a share in cash, roughly $11.3 billion of enterprise value, its largest life-sciences deal in more than a decade. June 25 was the single biggest session on TECH's tape in the whole stretch. Since then the stock has just been drifting up toward the bid; it sits around $72.31, about 70 cents under the offer.

In other words, TECH is not even the top price performer in the group it was grouped with. Fourth of eight on the year:

Contestant	YTD 2026 (paper points)	Trailing ~120-day tape
Revvity (RVTY)	133.0	+42.5%
Avantor (AVTR)	126.9	+78.4%
Bruker (BRKR)	123.1	+58.5%
Bio-Techne (TECH)	123.0	+36.9%
Waters (WAT)	109.2	+38.4%
Sotera Health (SHC)	107.1	+34.4%
Thermo Fisher (TMO)	106.5	+23.4%
Danaher (DHR)	93.3	+9.4%
The Rest (equal weight)	114.2	+40.7%

TECH's row is the only one written by a takeover, not by a market marking a live business. Drop the single bid day out of its trailing 120-day window and TECH is up roughly 14%; the basket is up roughly 41%. The compounding in this group ran through every scorecard except TECH's.

Mechanism board: where the compounding came from

Price alone cannot separate a takeover from an acceleration, so run the operating tape for the same quarter.

The Rest, the leaders: Waters reported total revenue of $1.645 billion with organic revenue up about 9% in constant currency, above the high end of its own guidance. Thermo Fisher grew 5% organically to $11.99 billion while adjusted EPS rose 13%. Sotera Health grew revenue 9.2%, raised its full-year outlook, and lifted adjusted EBITDA 10%. Revvity grew pro forma revenue 3% organically but delivered adjusted EPS above the high end of its guidance, an adjusted operating margin of 29.3% against a 27% outlook, and 117% cash conversion — quiet, high-grade compounding. Even the field's messiest row, Bruker — 2.8% organic growth but instrument bookings up 10%, punished with an 11.6% post-earnings drop — is a live franchise still arguing with its own guidance.

TECH's row:fourth-quarter revenue of $321.2 million, up 1% as reported and 3% organically; adjusted EPS of $0.52, down 1.9%. The full-year numbers draw the flatline: revenue of about $1.2 billion, flat on both bases, and adjusted EPS of $1.93, up 0.5%. Its one accelerating line, the Diagnostics & Spatial Biology segment, grew 8% organically but is only about a quarter of sales; the core Protein Sciences business grew 1% organically. And there is no forward tape to judge — no fiscal-2027 guidance, no earnings call, because the company is being sold. A rich asset — about 32% adjusted operating margin, roughly $292 million of full-year operating cash flow — with a growth engine that was, in its final independent quarter, ticking near zero.

Adjudication: what $73 actually is

Merck KGaA says the deal is immediately accretive to its sales growth and EBITDA margin, and accretive to EPS by year three. Read the multiple, not the press release: $73 for about $1.93 of trailing adjusted EPS is roughly 38 times trailing earnings, on about 9 times sales, for a franchise whose adjusted EPS grew half a percent last year. That is a portfolio price — a strategic buyer paying to fill a gap in its own toolkit as the life-science tools market inflects — not a price the operating numbers were earning as they went.

For anyone holding or watching TECH, the consequence is arithmetic, not thesis. The last 70 cents between the market and the $73 bid is a deal-closing question — regulatory approval, timing — and either way the equity's independent story has already run out of field. Where this quarter actually deposited value for a long-term-focused investor is in the unconquered operators still driving their own scoreboards.

Final bell (pre-resolution checkpoint)

• Price scoreboard: TECH ahead, about 123 to 114. The win is real and non-transferable — a terminal offer, not momentum.
• Mechanism board: The Rest. That is where the quarter's compounding originated — Waters' constant-currency growth, Thermo's EPS, Sotera's raised guide — evidence that still has to prove itself next quarter, which is more than TECH can say.
• Design lesson, one line: when a roundup names a "winner of the quarter," check whether the company did something in the quarter or a buyer did something to it — a takeover tombstone and an operating acceleration land in the same column of a winners-and-losers screen and mean opposite things for the future.

The card is frozen. Next checkpoint: the deal closes or it does not — and nothing in that binary is an operating bet anymore.